Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Anastrozole
Drug ID BADD_D00142
Description Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer.[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne.[A186865] Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as [tamoxifen].[A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863]
Indications and Usage For adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in post-menopausal women. Has also been used to treat pubertal gynecomastia and McCune-Albright syndrome; however, manufacturer states that efficacy for these indications have not been established.
Marketing Status Prescription; Discontinued
ATC Code L02BG03
DrugBank ID DB01217
KEGG ID D00960
MeSH ID D000077384
PubChem ID 2187
TTD Drug ID D0W0BF
NDC Product Code 63850-6527; 0395-8157; 68554-0026; 0310-0201; 71335-1879; 65129-1119; 16729-035; 68071-1682; 71052-248; 72789-008; 65096-0117; 51991-620; 59651-236; 65072-0702; 63629-5269; 16571-421; 63850-0010; 82393-201; 62135-490; 63187-080; 62559-670; 50090-2453; 58623-0041; 55111-814; 68382-209; 51927-4435; 68001-155; 50090-5002; 65841-743; 76420-004; 50268-075; 0093-7536; 61200-104; 42291-085; 46014-1160; 70518-2484; 73377-120; 69988-0013; 50090-5812; 62756-428; 62157-077; 70934-488; 70518-2420; 60429-286; 68071-5203; 60687-112; 51552-1568; 46014-1009; 38779-2555; 0904-6195; 43063-383; 60440-2921; 53104-7627; 62175-710
Synonyms Anastrozole | 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile) | Anastrazole | Arimidex | ICI D1033 | ZD-1033 | ZD 1033 | Zeneca ZD 1033 | ZD1033
Chemical Information
Molecular Formula C17H19N5
CAS Registry Number 120511-73-1
SMILES CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiovascular disorderAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
OsteoporosisAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
Urogenital disorderAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mesenteric vein thrombosis24.01.08.004; 07.15.02.0130.001131%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.011313%Not Available
Metastases to lymph nodes01.09.01.015; 16.22.02.0060.000787%Not Available
Metastases to pleura22.05.04.002; 16.22.02.0220.000197%Not Available
Pelvic prolapse21.07.05.0070.000754%Not Available
Recurrent cancer16.16.01.0150.001131%Not Available
Tumour marker increased13.22.01.0170.001131%Not Available
Metastases to heart16.22.02.016; 02.10.01.0020.000197%Not Available
Anti-neutrophil cytoplasmic antibody positive vasculitis24.05.02.016; 10.02.02.0230.000754%Not Available
Metastases to bone marrow16.22.02.013; 01.05.01.0220.000754%Not Available
Metastases to abdominal wall16.22.02.011; 07.16.05.0070.000295%Not Available
Non-alcoholic steatohepatitis14.08.04.024; 09.01.07.0350.001508%Not Available
Brain natriuretic peptide increased13.02.04.0110.000754%Not Available
Breast cancer metastatic21.05.01.016; 16.10.01.0080.001476%Not Available
Tenosynovitis stenosans15.04.02.0050.000754%Not Available
Vitreous adhesions06.09.01.0110.001131%Not Available
Subacute cutaneous lupus erythematosus23.03.02.020; 15.06.02.012; 10.04.03.0120.004902%Not Available
Insulin-like growth factor increased13.10.10.0040.001131%Not Available
Foot deformity15.10.03.0050.002263%Not Available
Grip strength decreased13.15.01.0410.000754%Not Available
Pneumonia cryptococcal22.07.08.012; 11.03.04.0050.000754%Not Available
Quality of life decreased13.18.01.0130.001508%Not Available
Skin plaque23.03.03.0440.000754%Not Available
Acquired gene mutation08.01.10.0020.001508%Not Available
Tooth demineralisation14.04.01.016; 07.09.05.0160.000754%Not Available
Portal fibrosis24.08.06.004; 09.01.04.0080.001131%Not Available
Pseudocirrhosis16.32.03.027; 09.01.04.0090.000393%Not Available
The 16th Page    First    Pre   16    Total 16 Pages